Literature DB >> 429327

Fractionation of low molecular weight heparin species and their interaction with antithrombin.

D Beeler, R Rosenberg, R Jordan.   

Abstract

Preparations of low molecular weight porcine heparin with an average specific anticoagulant activity of 94 units/mg were fractionated into "active" and "relatively inactive" forms of the mucopolysaccharide of approximately 6000 daltons each. The active fraction was further subdivided into various species with descending but significant affinities for the protease inhibitor as well as decreasing but substantial anticoagulatn potencies. "Highly active" heparin (approximately 8% of the low molecular weight pool) possesses a specific anticoagulant activity of 350 +/- 10 units/mg. The relatively inactive fraction (67% of the low molecular weight pool) exhibits a specific anticoagulant activity of 4 +/- 1 units/mg. The binding of highly active heparin to antithrombin is accurately described by a single-site binding model with a KHep-ATDISS of approximately 1 X 10(-7) M. Variations in this binding parameter secondary to changes in environmental variables indicate that charge-charge interactions as well as an increase in entropy are critical to the formation of the highly active heparin-antithrombin complex. The interaction of relatively inactive heparin with the protease inhibitor is characterized by an apparent KHep-ATDISS of 1 X 10(-4) M. In large measure, this is due to small amounts of residual active mucopolysaccharide (0.5%). The ability of the highly active heparin to accelerate the thrombin-antithrombin interaction was also examined. We were able to demonstrate that the mucopolysaccharide acts as a catalyst in this process and is able to initiate multiple rounds of enzyme-inhibitor complex formation. The rate of enzyme neutralization is increased to a maximum of 2300-fold as the concentration of heparin is raised until the inhibitor is saturated with mucopolysaccharide. Further increases in heparin concentration result in a reduction in the speed of enzyme neutralization. This appears to be due to the formation of thrombin-heparin complexes. A mathematical model is given which provides a relationship between the initial velocity of enzyme neutralization and reactant concentrations.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 429327

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Applications of phasor plots to in vitro protein studies.

Authors:  Nicholas G James; Justin A Ross; Martin Stefl; David M Jameson
Journal:  Anal Biochem       Date:  2010-11-13       Impact factor: 3.365

2.  Non-enzymatic glycation of type I collagen diminishes collagen-proteoglycan binding and weakens cell adhesion.

Authors:  Kristin L Reigle; Gloria Di Lullo; Kevin R Turner; Jerold A Last; Inna Chervoneva; David E Birk; James L Funderburgh; Elizabeth Elrod; Markus W Germann; Charles Surber; Ralph D Sanderson; James D San Antonio
Journal:  J Cell Biochem       Date:  2008-08-01       Impact factor: 4.429

3.  Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.

Authors:  Kristin M Bompiani; Jens L Lohrmann; George A Pitoc; James W Frederiksen; George B Mackensen; Bruce A Sullenger
Journal:  Chem Biol       Date:  2014-07-24

4.  Defining the domains of type I collagen involved in heparin- binding and endothelial tube formation.

Authors:  S M Sweeney; C A Guy; G B Fields; J D San Antonio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 5.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

6.  The heparin-catalysed inhibition of human factor XIa by antithrombin III is dependent on the heparin type.

Authors:  H Soons; G Tans; H C Hemker
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

7.  New heparin-like insoluble materials: part I.

Authors:  C Fougnot; J Jozefonvicz; M Samama; L Bara
Journal:  Ann Biomed Eng       Date:  1979       Impact factor: 3.934

8.  Detection of a new heparin-dependent inhibitor of thrombin in human plasma.

Authors:  D M Tollefsen; M K Blank
Journal:  J Clin Invest       Date:  1981-09       Impact factor: 14.808

9.  Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach.

Authors:  M K Lee; A D Lander
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

Review 10.  The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants.

Authors:  Andrew D Blann; Chee W Khoo
Journal:  Vasc Health Risk Manag       Date:  2009-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.